Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 3/20 | 0.54 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.47 |
| ▸ | MYC | P01106 | 2/20 | 0.45 |
| ▸ | MAX | P61244 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 7/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.41 |
| ▸ | GCK | P35557 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17775434 | 0.89 | EP300 (0.49) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL16369610 | 0.86 | EP300 (0.63) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL16369635 | 0.82 | MYC (0.62) | EP300MYCMAXHIF1ABRD4 | |
| SCHEMBL16392463 | 0.82 | EP300 (0.57) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL24379797 | 0.79 | EP300 (0.53) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL16392500 | 0.78 | EP300 (0.52) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL17784957 | 0.77 | EP300 (0.58) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL17784953 | 0.77 | EP300 (0.56) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL11980738 | 0.77 | EP300 (0.69) | EP300BCL2BCL2L1MCL1BAK1 | |
| SCHEMBL17775433 | 0.76 | MYC (0.54) | EP300MYCMAXHIF1ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793600-B2 | Cystobactamides | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-20190185514-A1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185514-A1 | CYSTOBACTAMIDES | CTH, SLC7A11, SULT2A1 | EP300 3359/4885BCL2 3703/4885BCL2L1 1668/4885 |
| US-10793600-B2 | Cystobactamides | CTH, SLC7A11, SULT2A1 | EP300 3514/4885BCL2 3856/4885BCL2L1 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.